Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics


Aridis Pharmaceuticals Inc. (ARDS): $1.02

0.01 (+0.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ARDS POWR Grades


  • ARDS scores best on the Sentiment dimension, with a Sentiment rank ahead of 79.53% of US stocks.
  • ARDS's strongest trending metric is Sentiment; it's been moving up over the last 48 days.
  • ARDS's current lowest rank is in the Stability metric (where it is better than 3.59% of US stocks).

ARDS Stock Summary

  • The ratio of debt to operating expenses for Aridis Pharmaceuticals Inc is higher than it is for about merely 0.5% of US stocks.
  • With a year-over-year growth in debt of -100%, Aridis Pharmaceuticals Inc's debt growth rate surpasses only 0% of about US stocks.
  • As for revenue growth, note that ARDS's revenue has grown -45.2% over the past 12 months; that beats the revenue growth of only 3.59% of US companies in our set.
  • Stocks that are quantitatively similar to ARDS, based on their financial statements, market capitalization, and price volatility, are ZYME, AUTL, PIRS, XCUR, and CDTX.
  • ARDS's SEC filings can be seen here. And to visit Aridis Pharmaceuticals Inc's official web site, go to www.aridispharma.com.

ARDS Valuation Summary

  • In comparison to the median Healthcare stock, ARDS's price/sales ratio is 12902.64% higher, now standing at 1475.8.
  • ARDS's price/sales ratio has moved up 1387.3 over the prior 37 months.
  • ARDS's price/sales ratio has moved up 1387.3 over the prior 37 months.

Below are key valuation metrics over time for ARDS.

Stock Date P/S P/B P/E EV/EBIT
ARDS 2021-08-31 1475.8 -3.6 -1.9 -1.9
ARDS 2021-08-30 1369.7 -3.4 -1.8 -1.7
ARDS 2021-08-27 1384.8 -3.4 -1.8 -1.7
ARDS 2021-08-26 1433.3 -3.5 -1.9 -1.8
ARDS 2021-08-25 1497.0 -3.7 -2.0 -1.9
ARDS 2021-08-24 1415.2 -3.5 -1.9 -1.8

ARDS Price Target

For more insight on analysts targets of ARDS, see our ARDS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.00 Average Broker Recommendation 1.5 (Moderate Buy)

ARDS Stock Price Chart Interactive Chart >

Price chart for ARDS

ARDS Price/Volume Stats

Current price $1.02 52-week high $7.72
Prev. close $1.01 52-week low $0.88
Day low $0.95 Volume 16,659
Day high $1.05 Avg. volume 970,378
50-day MA $1.36 Dividend yield N/A
200-day MA $2.43 Market Cap 18.01M

Aridis Pharmaceuticals Inc. (ARDS) Company Bio


Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.


ARDS Latest News Stream


Event/Time News Detail
Loading, please wait...

ARDS Latest Social Stream


Loading social stream, please wait...

View Full ARDS Social Stream

Latest ARDS News From Around the Web

Below are the latest news stories about Aridis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning!

William White on InvestorPlace | March 29, 2022

Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aridis Pharmaceuticals (ARDS – Research Report), with a price target of $19.00. The company's shares closed last Thursday at $2.80. According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.1% and a 36.1% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Citius Pharmaceuticals, and Achieve Life Sciences. Aridis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $16.67.

Catie Powers on TipRanks | February 17, 2022

Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study

Aridis Pharmaceuticals Inc''s (NASDAQ: ARDS ) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant . Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, … Full story available on Benzinga.com

Benzinga | February 17, 2022

Aridis, Rhythm top healthcare gainers; 10x Genomics, iSpecimen lead losers pack

Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. 10x Genomics (TXG) -16%. iSpecimen ISPC -10%.

Seeking Alpha | February 17, 2022

Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that both of its fully human monoclonal antibodies (mAbs) in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant. Moreover, both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration.

Yahoo | February 17, 2022

Read More 'ARDS' Stories Here

ARDS Price Returns

1-mo -20.31%
3-mo -53.00%
6-mo -57.32%
1-year -82.52%
3-year -89.06%
5-year N/A
YTD -56.22%
2021 -61.61%
2020 36.40%
2019 -59.87%
2018 N/A
2017 N/A

Continue Researching ARDS

Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:

Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.2187 seconds.